SCHEDULE: FMR LLC & Abigail Johnson Boost Stake in Stoke Therapeutics
Amendment to Beneficial Ownership Statement
FMR LLC and Abigail P. Johnson have reported a 12.5% beneficial ownership stake in Stoke Therapeutics Inc., as detailed in their latest Schedule 13G amendment.
Summary
- FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 6,865,057 shares of common stock in STOKE THERAPEUTICS INC.
- This aggregate amount represents 12.5% of the total outstanding common stock of STOKE THERAPEUTICS INC.
- FMR LLC holds sole voting power over 6,857,693 shares and sole dispositive power over 6,865,057 shares.
- Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same aggregate amount of shares.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously filed statement.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The disclosure of a 12.5% beneficial ownership by a major asset manager like FMR LLC, along with its CEO, Abigail P. Johnson, is generally viewed positively as it indicates strong institutional confidence and a substantial, long-term investment in the company.
Positives
- Significant institutional investment from FMR LLC, a major asset manager, signals confidence in STOKE THERAPEUTICS INC.
- The 12.5% stake indicates a substantial, long-term commitment from a prominent financial institution.
Negatives
- No explicit negatives are present in this type of filing, which primarily focuses on beneficial ownership disclosure.
Risks
- No specific risks related to STOKE THERAPEUTICS INC's operations or financial health are detailed in this ownership disclosure.
Future Outlook
NA
Management Comments
- "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."
Industry Context
This filing reflects a significant institutional investor's continued or increased stake in STOKE THERAPEUTICS INC, a common occurrence in the biotechnology or pharmaceutical sector where long-term investment in promising therapies is typical. Such large stakes by major asset managers like FMR LLC can be seen as a vote of confidence in the company's potential within its competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Clarification | Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, along with other Johnson family members, are predominant owners of FMR LLC's Series B voting common shares (49% voting power). A shareholders' voting agreement ensures all Series B shares are voted in accordance with the majority, potentially deeming the Johnson family a controlling group for FMR LLC. | NA | This clarifies the control structure within FMR LLC, which in turn controls the reported beneficial ownership in STOKE THERAPEUTICS INC. It does not represent a change in STOKE THERAPEUTICS INC's corporate governance but provides transparency on the ultimate control of the reported shares. |
Related Party Transactions
- The filing explicitly states that Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same shares as FMR LLC, highlighting the relationship between the two reporting persons.
Stakeholder Impact
- Shareholders: Increased confidence due to significant institutional backing, potentially leading to positive share price movement.
- Management: Validation of company strategy and performance from a major investor.
- Employees: Potential for increased stability and resources if the investment signals long-term growth.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-10 | Filing date of Schedule 13G by FMR LLC, referencing Power of Attorney accession number -23-000003. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2023-01-31 | Filing date of Schedule 13G by FMR LLC, referencing Power of Attorney accession number -23-000038 for Abigail P. Johnson. |
| 2025-09-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-11-04 | Signature date for FMR LLC and Abigail P. Johnson on the Schedule 13G Amendment No. 2. |
Recommendation
holdThe filing indicates a substantial 12.5% beneficial ownership by FMR LLC and Abigail P. Johnson in STOKE THERAPEUTICS INC. This significant institutional stake is generally a positive indicator, suggesting confidence from a major asset manager. However, a Schedule 13G is solely an ownership disclosure and does not provide financial performance, operational updates, or strategic guidance for STOKE THERAPEUTICS INC. Therefore, while the institutional backing is favorable, there is insufficient information within this filing alone to make a definitive 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate, pending further analysis of the company's financial results, pipeline, and market position.
Keywords
STOKE THERAPEUTICS INC, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.